Table 3 from A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
Most common AEs (occurring in ≥10% of subjects) considered related to sotigalimab by the investigator (n = 33)
创建时间：
2025-02-21
